Special Issue

Innate T Cells in Cancer Immunity

Message from the Guest Editor

Although T cells are traditionally viewed as adaptive immune cells, a large body of evidence has defined many different T cell subsets that display bona fide innate functionality. Thus, we know that in both mice and humans, gamma delta (□□) T cells, natural killer T (NKT) cells, and mucosal associated invariant T (MAIT) cells are all part of a diverse innate immune system. These lymphocytes are often the first responders during infection and inflammation and can promote type 1, type 2 or type 3 immune responses depending on the specific stimuli and microenvironment they encounter. In this Special Issue, we are seeking articles (reviews or original research) on the biology of innate T cells in relation to cancer. This may include mechanistic studies on the pro- and antitumor properties of innate T cells, or their role in cancer immunotherapy.

Guest Editor

Dr. Vasileios Bekiaris
Department of Health Technology, Technical University of Denmark, Denmark

Deadline for manuscript submissions

closed (31 July 2021)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/53203

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)